JANX250117P90000
- 0.00
- 0.000.00%
Janux Therapeutics Newsroom
Clear Street Launches Healthcare & Biotechnology Equity Research
Janux Therapeutics Price Target Maintained With a $200.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
BTIG Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Kura Oncology (KURA)
Express News | Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Scotiabank Maintains Janux Therapeutics(JANX.US) With Hold Rating, Raises Target Price to $62
TD Cowen Remains a Buy on Janux Therapeutics Inc (JANX)
Janux Therapeutics Inc's Promising Data and Strategic Advancements Earn a Reiterated Buy Rating
Janux Therapeutics Offering Is Expected to Close Around Dec. 6 >JANX
Janux Therapeutics Plans to Use Proceeds for Clinical Development of Internal Product Pipeline, General Corporate Purposes >JANX
Why Janux Therapeutics Crushed the Market Today
Scotiabank Maintains Sector Perform on Janux Therapeutics, Raises Price Target to $62
JANX Stock Hits Record High on Prostate Cancer Study Data
News Highlights: Top Company News of the Day - Wednesday at 1 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Janux Therapeutics Commences Underwritten Public Offering Of $300M Of Shares Of Its Common Stock